A pioneering arenavirus platform
Our proprietary, flexible platform can engineer arenaviral therapeutics that mobilize and amplify targeted T cells and antibodies, the body’s natural infection killers, to fight or prevent serious disease.
A potential new class of immuno-therapeutics
Published pre-clinical data show our arenaviral therapeutics induce a robust antigen-specific T cell response not achieved by other immunotherapy approaches, leading to tumor cures and long-term immunity.
Driving a robust T cell response
Preliminary immunogenicity data presented at AACR show our lead oncology candidates, HB-201 and HB-202, induce a strong antigen-specific T cell response, with a robust increase in HPV16+-specific T cells after just one dose.
Clinical efficacy for HPV16+ cancers
Early Phase 1 data evaluating HB-201 show encouraging efficacy signals and response rates, as well as positive safety and tolerability, highlighting its potential as a novel and effective immunotherapy for a difficult-to-treat patient population.
Oops, an error occurred! Code: 20210922224234a85c40d8
The source of HOOKIPA’s strength lies in our people and the skills and experience that they bring.
We want to continue to grow fast as a company and nurture a respectful and diverse culture that encourages teamwork. Attracting and retaining the best people is essential to achieve this. Please get in touch with us to find out more about our career opportunities.